Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
Author:
Publisher
Elsevier BV
Subject
Pharmacology
Reference72 articles.
1. NCCN guidelines insights: non-small cell lung cancer, version 1.2020;Ettinger;J. Natl. Compr. Cancer Netw.,2019
2. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
3. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients;Remon;Ann. Oncol.,2018
4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;New Engl. J. Med.,2018
5. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC;Le;Clin. Cancer Res,2018
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02
2. MET fusions are targetable genomic variants in the treatment of advanced malignancies;Cell Communication and Signaling;2024-01-09
3. MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance;Drug Resistance Updates;2024-01
4. c-Met pathway in human malignancies and its targeting by natural compounds for cancer therapy;Phytomedicine;2024-01
5. Mechanisms analysis for Formononetin counteracted‐Osimertinib resistance in non‐small cell lung cancer cells: From the insight into the gene transcriptional level;Chemical Biology & Drug Design;2023-12-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3